However, analysts at HDFC Securities are underconfident about Dr. Reddy’s outlook, as beyond Revlimid, there is insufficient pipeline visibility to sustain growth and margin momentum, raising concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback